Home / Brands / Amerisource Health Services
Amerisource Health Services Recalls
69 recalls on record · January 20, 2016 to May 27, 2026 · Drugs
Recalls by year
16
17
22
23
24
25
26
Count of recall notices naming this brand, by the year the recall was announced. A quiet year is not proof of a safe year.
May 27, 2026DrugsFDA
Amerisource Health Services LLC recalls Primidone Tablets, USP, 50 mg, 100 Tablets (10 x 10 unit dose blister) per carton, Rx only, Distributed by: American Hea
Hazard: Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.
May 27, 2026DrugsFDA
Amerisource Health Services LLC recalls Primidone Tablets, USP, 250 mg, 100 Tablets (10 x 10 unit dose blister) per carton, Rx only, Distributed by: American He
Hazard: Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.
April 1, 2026DrugsFDA
Amerisource Health Services LLC recalls Meclizine Hydrochloride Tablets, USP 12.5 mg, (a) 50 Tablets [5 x 10] (NDC 60687-775-65) (b) 12.5 mg Individual Dose ( N
Hazard: Failed tablet specifications.
February 18, 2026DrugsFDA
Amerisource Health Services LLC recalls Oxycodone Hydrochloride Tablets, USP (CII), 5 mg, 100-Count (10 x 10) blister cards per carton, Rx Only, The drug prod
Hazard: Defective container: card seal defects (weak/non-existent seals), leading to the tablets falling out of their cavities.
November 5, 2025DrugsFDA
Amerisource Health Services LLC recalls Prazosin Hydrochloride, Capsules, USP, 5 mg, 20 capsules (5x4) cartons, Rx only, Distributed by American Health Packagin
Hazard: Failed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit
November 5, 2025DrugsFDA
Amerisource Health Services LLC recalls Prazosin Hydrochloride, Capsules, USP, 2 mg, 100 capsules (10x10) cartons, Rx only, Distributed by American Health Packa
Hazard: Failed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit
November 5, 2025DrugsFDA
Amerisource Health Services LLC recalls Prazosin Hydrochloride, Capsules, USP, 1 mg, 100 capsules (10x10) cartons, Rx only, Distributed by American Health Packa
Hazard: Failed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit
October 22, 2025DrugsFDA
Amerisource Health Services LLC recalls Sucralfate Tablets, USP 1 gram, 100 Tablets, (10x10), Rx Only, Distributed by: American Health Packaging, Columbus, Ohio
Hazard: CGMP Deviations: The recalling firm filed for Chapter 11 on September 30, 2024. As a result, it cannot monitor the quality program and hence cannot assure that products meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess, rendering the products adulterated.
October 8, 2025DrugsFDA
Amerisource Health Services LLC recalls Carbamazepine Extended-Release Tablets, USP 400 mg, 30 Tablets per carton (3x10 unit dose cards), Rx Only, American Heal
Hazard: Failed Dissolution Specifications.
September 24, 2025DrugsFDA
Amerisource Health Services LLC recalls chlorproMAZINE Hydrochloride Tablets, USP, 200 mg, 100 (10x10) blisterpack per carton, Rx Only, Distributed by: American
Hazard: Presence of a foreign substance.A specific lot of auxiliary polyester coil, used in product packaging at the manufacturing site, was detected with presence of a micro-organism. No micro-organism was detected on any tablets.
September 24, 2025DrugsFDA
Amerisource Health Services LLC recalls chlorproMAZINE Hydrochloride Tablets, USP, 100 mg, 100 (10x10) blisterpack per carton, Rx Only, Distributed by: American
Hazard: Presence of a foreign substance.A specific lot of auxiliary polyester coil, used in product packaging at the manufacturing site, was detected with presence of a micro-organism. No micro-organism was detected on any tablets.
September 24, 2025DrugsFDA
Amerisource Health Services LLC recalls chlorproMAZINE Hydrochloride Tablets, USP, 50 mg, 100 (10x10) blisterpacks, Rx Only, Distributed by: American Health Pac
Hazard: Presence of a foreign substance.A specific lot of auxiliary polyester coil, used in product packaging at the manufacturing site, was detected with presence of a micro-organism. No micro-organism was detected on any tablets.
September 24, 2025DrugsFDA
Amerisource Health Services LLC recalls chlorproMAZINE Hydrochloride Tablets, USP, 25 mg, packaged as a) 50 (5x10) blisterpacks, NDC: 60687-430-65; (Individual
Hazard: Presence of a foreign substance.A specific lot of auxiliary polyester coil, used in product packaging at the manufacturing site, was detected with presence of a micro-organism. No micro-organism was detected on any tablets.
September 3, 2025DrugsFDA
Amerisource Health Services LLC recalls Sucralfate Tablets, USP 1 gram, 100 Tablets, (10x10), Rx Only, Distributed by: American Health Packaging, Columbus, Ohio
Hazard: CGMP Deviations: The recalling firm filed for Chapter 11 in September 2024. As a result, it cannot monitor the quality program and hence cannot assure that products meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess, rendering the products adulterated.
June 11, 2025DrugsFDA
Amerisource Health Services LLC recalls Indomethacin Extended-Release Capsules, USP, 75 mg, 30 capsules (3 x 10 blister cards) per carton, Rx Only, Distributed
Hazard: cGMP deviations
April 30, 2025DrugsFDA
Amerisource Health Services LLC recalls Haloperidol Decanoate Injection, 100mg/mL*, 5 x 1 mL Single-Dose Vials, Rx Only, Manufactured by: Somerset Therapeutics
Hazard: Lack of assurance of sterility. Bacterial contamination detected in some media fill units
April 30, 2025DrugsFDA
Amerisource Health Services LLC recalls Haloperidol Decanoate Injection, 100 mg/mL*, 1 x 1 mL Single-Dose Vial, Rx only, Manufactured by: Somerset Therapeutics
Hazard: Lack of assurance of sterility. Bacterial contamination detected in some media fill units
April 30, 2025DrugsFDA
Amerisource Health Services LLC recalls Haloperidol Decanoate Injection, 50mg/mL* , 1 mL Single-Dose Vial, Rx only, Manufactured by Somerset Therapeutics Limite
Hazard: Lack of assurance of sterility. Bacterial contamination detected in some media fill units
April 9, 2025DrugsFDA
Amerisource Health Services LLC recalls Voriconazole Tablets, 50 mg, packaged in cartons of 3 blister cards with 10 individual blistered doses (30 Unit Dose per
Hazard: cGMP Deviations: Received notification from their supplier requesting they perform a recall due to the fact they repackaged the product.
January 22, 2025DrugsFDA
Amerisource Health Services LLC recalls glipiZIDE, Extended-Release Tablets, 2.5 mg, 30-count (3x10 blister cards) carton, Rx Only, Distributed by: American Hea
Hazard: Failed Dissolution Specifications:
January 22, 2025DrugsFDA
Amerisource Health Services LLC recalls Clobazam Tablets, 10 mg, packaged in 30 tablets per carton (3x10 blister cards each), Rx Only, Amneal Pharmaceuticals LL
Hazard: Presence of Foreign Tablets/Capsules
January 15, 2025DrugsFDA
Amerisource Health Services LLC recalls Clobazam Tablets, 10 mg, packaged in 30 tablets per carton (3x10 blister cards each), Rx Only, Amneal Pharmaceuticals LL
Hazard: Presence of Foreign Tablets/Capsules
January 1, 2025DrugsFDA
Amerisource Health Services LLC recalls Duloxetine Delayed-Release Capsules, USP, 60 mg, Rx only, 1,000 count bottles, Manufactured by: Aurobindo Pharma Limited
Hazard: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit.
January 1, 2025DrugsFDA
Amerisource Health Services LLC recalls Duloxetine Delayed-Release Capsules USP, 60 mg, Rx only, 30 count bottles, Manufactured by: Aurobindo Pharma Limited, Hy
Hazard: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit.
January 1, 2025DrugsFDA
Amerisource Health Services LLC recalls Duloxetine Delayed-Release Capsules, USP, 30 mg, Rx only, 90 count bottles, Manufactured by: Aurobindo Pharma Limited, H
Hazard: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit.
January 1, 2025DrugsFDA
Amerisource Health Services LLC recalls Duloxetine Delayed-Release Capsules USP, 30 mg, Rx only, 30 count bottles, Manufactured by: Aurobindo Pharma Limited, Hy
Hazard: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit.
December 11, 2024DrugsFDA
Amerisource Health Services LLC recalls Duloxetine Delayed-Release Capsules, USP, 60 mg, Rx only, 1,000 count bottle, Manufactured by: Aurobindo Pharma Limited,
Hazard: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit
December 11, 2024DrugsFDA
Amerisource Health Services LLC recalls Duloxetine Delayed-Release Capsules, USP, 30 mg, Rx only, a) 30 count (NDC 68001-414-04) and b) 1,000 count (NDC 68001-4
Hazard: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit
December 11, 2024DrugsFDA
Amerisource Health Services LLC recalls Duloxetine Delayed-Release Capsules, USP, 20 mg, Rx only, 60 count bottles, Manufactured by: Aurobindo Pharma Limited, H
Hazard: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit
August 7, 2024DrugsFDA
Amerisource Health Services LLC recalls Potassium Chloride Extended-Release Capsules, USP, (750 mg) 10 mEq K, a).100-count bottle ( NDC 68001-396-00), b) 500-co
Hazard: Failed Dissolution Specifications